Please login to the form below

Not currently logged in
Email:
Password:

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial
EU

Guidance on the way first-in-human (FIH) trials should be conducted and managed needs to be updated to reduce the risks to study participants, says the EMA.

The EU drugs regulator has just published a new concept paper - open for comment until 30 September - that lays out a framework for revision of the current 2007 guidelines on FIH trials.

The move comes in the wake of the trial in France earlier this year that resulted in one volunteer's death and put five others in hospital.

A subsequent inquiry by the French government put contract research organisation (CRO) Biotrial and pharmaceutical sponsor Bial at fault for the failings in the study and led to calls for tightened up FIH regulations in Europe - although this is disputed by the companies.

The 2007 guideline covers strategies to "identify and mitigate risk" in FIH trials but no longer accommodates increasingly complex trial protocols, including a shift towards combining safety analysis with preliminary proof-of-concept measures, using both single and multiple ascending doses and recruiting patients across wider age ranges, says the concept paper.

"In recent years, the practice for conducting first-in-human clinical trials has evolved towards a more integrated approach, with sponsors conducting several steps of clinical development within a single clinical trial protocol," said the EMA in a statement.

The concept paper describes use of incremental decisions - based on the data collected at each previous step - to help mitigate risks. It also calls for greater sophistication in the guideline to take into account "the specificities of each medicine, its mechanism of action, and intended therapeutic use".

The EMA makes specific reference to the French trial, saying the review "takes into account the lessons learnt from the tragic incident".

The paper was developed by the EMA in collaboration with the European Commission and regulatory experts from EU member states, and will be used along with comments to prepare a new draft of the 2007 guideline, likely before the end of the year.

Article by
Phil Taylor

22nd July 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics